Acknowledgments
The Abbott reagents used in the method evaluation were provided by Abbott Diagnostic Laboratories.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: MB is an employee of Abbott. VK serves as a consultant for Abbott. The other authors have declared no conflicts of interest.
-
Informed consent: Informed consent was deemed not applicable as these were surplus samples used in this study.
-
Ethical approval: Institutional Review Board at the University Health Network in Toronto, Ontario, Canada deemed the study exempt from review.
References
1. Bell, L, Hunter, AL, Kyriacou, A, Mukherjee, A, Syed, AA. Clinical diagnosis of Graves’ or non-Graves’ hyperthyroidism compared to TSH receptor antibody test. Endocr Connect 2018;7:504–10. https://doi.org/10.1530/ec-18-0082.Search in Google Scholar
2. Scappaticcio, L, Trimboli, P, Keller, F, Imperiali, M, Piccardo, A, Giovanella, L. Diagnostic testing for Graves’ or non-Graves’ hyperthyroidism: a comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol 2020;92:169–78. https://doi.org/10.1111/cen.14130.Search in Google Scholar PubMed
3. Kim, J, Choi, MS, Park, J, Park, H, Jang, HW, Choe, JH, et al.. Changes in thyrotropin receptor antibody levels following total thyroidectomy or radioiodine therapy in patients with refractory Graves’ Disease. Thyroid 2021;31:1264–71. https://doi.org/10.1089/thy.2020.0756.Search in Google Scholar PubMed PubMed Central
4. Vos, XG, Endert, E, Zwinderman, AH, Tijssen, JGP, Wiersinga, WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 2016;101:1381–9. https://doi.org/10.1210/jc.2015-3644.Search in Google Scholar PubMed
5. Takasu, N, Yamashiro, K, Komiya, I, Ochi, Y, Sato, Y, Nagata, A. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 2000;10:891–6. https://doi.org/10.1089/thy.2000.10.891.Search in Google Scholar PubMed
6. Ide, A, Amino, N, Nishihara, E, Kudo, T, Ito, M, Kimura, Y, et al.. Partial prediction of postpartum Graves’ thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy. Endocr J 2016;63:929–32. https://doi.org/10.1507/endocrj.ej16-0296.Search in Google Scholar
7. De Groot, L, Abalovich, M, Alexander, EK, Amino, N, Barbour, L, Cobin, RH, et al.. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543–65. https://doi.org/10.1210/jc.2011-2803.Search in Google Scholar PubMed
8. Nakano, M, Konishi, H, Koshiba, M. Thyroid-Stimulating antibody/thyroid-stimulating hormone receptor antibody ratio as a sensitive screening test for active Graves’ orbitopathy. Endocr Pract 2022;28:1050–4.10.1016/j.eprac.2022.07.007Search in Google Scholar PubMed
9. Diana, T, Wüster, C, Kanitz, M, Kahaly, GJ. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016;39:1159–65. https://doi.org/10.1007/s40618-016-0478-9.Search in Google Scholar PubMed
10. Higgins, V, Patel, K, Kulasingam, V, Beriault, DR, Rutledge, AC, Selvaratnam, R. Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. Clin Biochem 2020;86:56–60. https://doi.org/10.1016/j.clinbiochem.2020.08.007.Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
